• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国囊性纤维化的死亡率趋势

Cystic fibrosis mortality trends in France.

作者信息

Bellis Gil, Cazes Marie-Hélène, Parant Alain, Gaimard Maryse, Travers Cécile, Le Roux Evelyne, Ravilly Sophie, Rault Gilles

机构信息

Institut national d'études démographiques, 133 boulevard Davout, 75980 Paris Cedex 20, France.

出版信息

J Cyst Fibros. 2007 May;6(3):179-86. doi: 10.1016/j.jcf.2006.07.001. Epub 2006 Aug 17.

DOI:10.1016/j.jcf.2006.07.001
PMID:16916626
Abstract

BACKGROUND

In 1992 France set up a national cystic fibrosis observatory (Observatoire national de la mucoviscidose, ONM) to monitor the state of health of patients on an annual basis. Using the ONM data, this study estimates the main indicators for life expectancy and assesses the total number of cystic fibrosis patients.

METHODS

The data for the years 1994 to 2003 are divided into 3-year periods. Life tables are drawn up for these periods, from which mean and median lengths of life are determined. Using the most recent life table, the number of births in 2003 and the incidence of the disease, the total population of patients can be estimated, assuming a stationary population.

RESULTS

In 2001-2003, life expectancy at birth of patients registered with the ONM was 39.1 years and median length of life was 36.4 years. These results, substantially better than those of 1994-1996, are linked to improved conditions of patient inclusion in the ONM database, to improvements in their healthcare, but also to the limitations of the life tables. Based on the 2003 data, the total theoretical number of patients is 6490, and coverage by the ONM database is thus 63.2%.

CONCLUSIONS

These provisional results demonstrate the need to convert the ONM observatory into a registry providing exhaustive coverage of all patients.

摘要

背景

1992年,法国设立了国家囊性纤维化监测站(国家黏液黏稠病监测站,ONM),以便每年监测患者的健康状况。本研究利用ONM的数据估算了预期寿命的主要指标,并评估了囊性纤维化患者的总数。

方法

1994年至2003年的数据被划分为3年时间段。为这些时间段编制生命表,从中确定平均寿命和中位寿命。利用最新的生命表、2003年的出生人数和疾病发病率,假设人口稳定,可估算出患者的总人口数。

结果

在2001 - 2003年,在ONM登记的患者出生时的预期寿命为39.1岁,中位寿命为36.4岁。这些结果比1994 - 1996年的结果有显著改善,这与ONM数据库中患者纳入条件的改善、医疗保健的改善以及生命表的局限性有关。根据2003年的数据,患者的理论总数为6490人,因此ONM数据库的覆盖率为63.2%。

结论

这些初步结果表明,有必要将ONM监测站转变为一个能全面覆盖所有患者的登记机构。

相似文献

1
Cystic fibrosis mortality trends in France.法国囊性纤维化的死亡率趋势
J Cyst Fibros. 2007 May;6(3):179-86. doi: 10.1016/j.jcf.2006.07.001. Epub 2006 Aug 17.
2
Cystic fibrosis mortality: registry data of cystic fibrosis.囊性纤维化死亡率:囊性纤维化登记数据
J Insur Med. 1997;29(4):233-9.
3
Improved survival among young patients with cystic fibrosis.囊性纤维化年轻患者的生存率提高。
J Pediatr. 2003 Jun;142(6):631-6. doi: 10.1067/mpd.2003.197.
4
[The Italian registry for cystic fibrosis: what has changed in the last decade].[意大利囊性纤维化注册登记:过去十年有哪些变化]
Epidemiol Prev. 2003 Mar-Apr;27(2):91-6.
5
Deaths: final data for 2004.死亡情况:2004年最终数据。
Natl Vital Stat Rep. 2007 Aug 21;55(19):1-119.
6
Progression of mean age and mean expected mortality rate by duration of follow up in cohorts with a wide range of age.在年龄范围广泛的队列中,按随访时间划分的平均年龄和平均预期死亡率的变化情况。
J Insur Med. 2006;38(3):181-91.
7
[Measure of premature mortality: comparison of deaths before age 65 and expected years of life lost].[过早死亡率的衡量:65岁之前死亡情况与预期寿命损失年数的比较]
Rev Epidemiol Sante Publique. 2008 Aug;56(4):245-52. doi: 10.1016/j.respe.2008.05.025. Epub 2008 Aug 5.
8
Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.在法国两个参考医疗中心对囊性纤维化患者进行家庭和医院护理的费用。
Int J Technol Assess Health Care. 2006 Fall;22(4):525-31. doi: 10.1017/S0266462306051476.
9
[Mucoviscidosis: comparative analysis of epidemiological data of French and North American registries].
Rev Pneumol Clin. 1995;51(3):115-21.
10
United States life tables, 2004.美国生命表,2004年。
Natl Vital Stat Rep. 2007 Dec 28;56(9):1-39.

引用本文的文献

1
Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.CFTR调节剂对囊性纤维化患者长期生存及死亡率的影响:综述与二次分析
Pulm Ther. 2025 Jul 11. doi: 10.1007/s41030-025-00303-4.
2
Oral health and related outcomes in children and adolescents with cystic fibrosis: a scoping review.囊性纤维化患儿和青少年的口腔健康及相关结果:范围综述。
Eur Arch Paediatr Dent. 2024 Aug;25(4):455-469. doi: 10.1007/s40368-024-00885-8. Epub 2024 Jul 11.
3
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
英国非住院囊性纤维化患者的社会经济成本及健康相关生活质量
BMC Health Serv Res. 2015 Sep 28;15:428. doi: 10.1186/s12913-015-1061-3.
4
Management issues for adolescents with cystic fibrosis.囊性纤维化青少年的管理问题
Pulm Med. 2012;2012:134132. doi: 10.1155/2012/134132. Epub 2012 Sep 6.
5
Disease modifying anti-rheumatic drugs in people with cystic fibrosis-related arthritis.用于患有囊性纤维化相关性关节炎患者的改善病情抗风湿药。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD007336. doi: 10.1002/14651858.CD007336.pub3.
6
Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis.验证和使用参数模型来预测囊性纤维化患者的生存情况,超越观察数据:一项出生队列分析。
Thorax. 2011 Aug;66(8):674-9. doi: 10.1136/thoraxjnl-2011-200038. Epub 2011 Jun 8.
7
Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis.地衣芽枝孢菌:囊性纤维化患者中的一种新出现的病原体。
J Clin Microbiol. 2010 Jul;48(7):2381-6. doi: 10.1128/JCM.00047-10. Epub 2010 May 12.
8
Diabetes as a determinant of mortality in cystic fibrosis.糖尿病作为囊性纤维化患者死亡的决定因素。
Diabetes Care. 2010 Feb;33(2):311-6. doi: 10.2337/dc09-1215. Epub 2009 Nov 16.
9
Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.囊性纤维化患者的早期葡萄糖异常先于体重增长不良。
Diabetes Care. 2010 Feb;33(2):221-6. doi: 10.2337/dc09-1492. Epub 2009 Nov 12.
10
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.测量和改善囊性纤维化肺病的呼吸结局:治疗的机遇和挑战。
J Cyst Fibros. 2010 Jan;9(1):1-16. doi: 10.1016/j.jcf.2009.09.003. Epub 2009 Oct 14.